OCEA
Ocean Biomedical, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 7,780 |
Stock Information
| Shares Outstanding | 232.37M |
| Total Debt | $15.35M |
| Net Income | $-30.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $46K |
| EPS (TTM) | $-0.91 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Income | $-30.72M |
| Book/sh | $-0.56 |
| Employees | 7 |
Financial Ratios
| Current Ratio | 0.06 |
Returns & Margins
| ROA | -114.87% |
Ownership
| Insider Ownership | 10.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.00 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 66.67 |
| ATR | 0.0001 |
| Shares Float | 208.41M |
| Short Float | 2.05% |
| Short Ratio | 0.05 |
| Volatility | -0.33 |
| Rel Volume | 0.12 |
Performance History
| Week | -33.33% |
| Month | -33.33% |
| Quarter | -77.78% |
| 6 Months | -66.67% |
| YTD | -84.62% |
| Year | -97.29% |
| 3 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.00 | 5,265 |
| 2026-06-17 | $0.00 | 15,088 |
| 2026-06-16 | $0.00 | 23,098 |
| 2026-06-15 | $0.00 | 167,974 |
| 2026-06-12 | $0.00 | 40,581 |
| 2026-06-11 | $0.00 | 108 |
| 2026-06-10 | $0.00 | 2,148 |
| 2026-06-09 | $0.00 | 40,527 |
| 2026-06-08 | $0.00 | 52,524 |
| 2026-06-05 | $0.00 | 5,974 |
| 2026-06-04 | $0.00 | 8,810 |
| 2026-06-03 | $0.00 | 15,253 |
| 2026-06-02 | $0.00 | 37,816 |
| 2026-06-01 | $0.00 | 34,392 |
| 2026-05-29 | $0.00 | 178,619 |
| 2026-05-28 | $0.00 | 15,212 |
| 2026-05-27 | $0.00 | 174,284 |
| 2026-05-26 | $0.00 | 19,177 |
| 2026-05-22 | $0.00 | 51,493 |
| 2026-05-21 | $0.00 | 26,686 |
| 2026-05-20 | $0.00 | 421 |
| 2026-05-19 | $0.00 | 67,402 |
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
đ° Latest News
No news articles available at the moment. Check back later for updates on OCEA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $2,046,000 | $1,762,000 | $1,243,000 | - |
| Total Expenses | $3,798,000 | $10,214,000 | $16,121,000 | $62,345,000 |
| Other Income Expense | $-3,636,000 | $-102,490,000 | $5,000 | $1,000 |
| Other Non Operating Income Expenses | $3,558,000 | $-1,518,000 | $5,000 | $1,000 |
| Net Non Operating Interest Income Expense | $-2,046,000 | $-1,762,000 | $-1,243,000 | - |
| Interest Expense Non Operating | $2,046,000 | $1,762,000 | $1,243,000 | - |
| Operating Expense | $3,798,000 | $10,214,000 | $16,121,000 | $62,345,000 |
| General And Administrative Expense | $3,772,000 | $9,505,000 | $7,712,000 | $28,412,000 |
| Other Operating Expenses | - | - | $2,481,639 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Net Interest Income | $-2,046,000 | $-1,762,000 | $-1,243,000 | - |
| Normalized Income | $-5,587,000 | $-14,202,000 | $-17,359,000 | $-62,344,000 |
| Net Income From Continuing And Discontinued Operation | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Total Operating Income As Reported | $-3,798,000 | $-10,214,000 | $-16,121,000 | $-62,345,000 |
| Net Income Common Stockholders | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Net Income | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Net Income Including Noncontrolling Interests | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Net Income Continuous Operations | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Pretax Income | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Special Income Charges | $-356,000 | $-36,488,000 | $0 | - |
| Earnings From Equity Interest | $-3,301,000 | $-708,000 | - | - |
| Operating Income | $-3,798,000 | $-10,214,000 | $-16,121,000 | $-62,345,000 |
| Interest Income | - | - | $1,523,900 | - |
| Interest Income Non Operating | - | - | $1,523,900 | - |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-4.35 | $-0.86 | $-3.09 |
| Basic EPS | $-0.34 | $-4.35 | $-0.86 | $-3.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,541,000 | $-12,440,000 | $-16,116,000 | $-62,345,000 |
| Total Unusual Items | $-3,893,000 | $-100,264,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-3,893,000 | $-100,264,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-7,434,000 | $-112,704,000 | $-16,116,000 | $-62,345,000 |
| EBIT | $-7,434,000 | $-112,704,000 | $-16,116,000 | $-62,345,000 |
| Diluted Average Shares | $27,502,537 | $26,292,438 | $36,496,413 | $20,203,440 |
| Basic Average Shares | $27,502,537 | $26,292,438 | $36,496,413 | $20,203,440 |
| Diluted NI Availto Com Stockholders | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Restructuring And Mergern Acquisition | $356,000 | $21,408,000 | $0 | - |
| Gain On Sale Of Security | $-3,537,000 | $-63,776,000 | - | - |
| Research And Development | $26,000 | $709,000 | $8,409,000 | $33,933,000 |
| Selling General And Administration | $3,772,000 | $9,505,000 | $7,712,000 | $28,412,000 |
| Other Gand A | $3,772,000 | $9,505,000 | $7,712,000 | $28,412,000 |
| Other Special Charges | - | $15,080,000 | - | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Total Assets | $902,000 | $5,501,000 | $1,842,000 | $108,652,342 |
| Total Non Current Assets | $90,000 | $3,392,000 | $0 | $107,102,449 |
| Current Assets | $812,000 | $2,109,000 | $1,842,000 | $1,549,893 |
| Restricted Cash | $224,000 | $1,000,000 | $0 | - |
| Prepaid Assets | $588,000 | $1,105,000 | $0 | $474,291 |
| Cash Cash Equivalents And Short Term Investments | $0 | $4,000 | $34,000 | $1,075,602 |
| Cash And Cash Equivalents | $0 | $4,000 | $34,000 | $1,075,602 |
| Cash Financial | $0 | $4,000 | $34,000 | $1,075,602 |
| Current Deferred Assets | - | $0 | $1,808,000 | $19,000 |
| Other Non Current Assets | - | - | $110,443,335 | $107,102,449 |
| Receivables | - | - | $50,000 | $0 |
| Debt | ||||
| Net Debt | $16,300,000 | $12,114,000 | $742,000 | - |
| Total Debt | $16,300,000 | $12,118,000 | $776,000 | - |
| Current Debt And Capital Lease Obligation | $16,300,000 | $12,118,000 | $776,000 | - |
| Current Debt | $16,300,000 | $12,118,000 | $776,000 | - |
| Other Current Borrowings | $14,075,000 | $8,318,000 | $776,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $98,518,000 | $96,264,000 | $12,661,000 | $3,396,444 |
| Total Non Current Liabilities Net Minority Interest | $64,629,000 | $66,252,000 | $0 | $3,150,000 |
| Other Non Current Liabilities | $5,573,000 | $7,729,000 | - | - |
| Derivative Product Liabilities | $59,056,000 | $58,523,000 | $0 | - |
| Current Liabilities | $33,889,000 | $30,012,000 | $12,661,000 | $246,444 |
| Other Current Liabilities | $1,089,000 | $763,000 | - | - |
| Current Notes Payable | $2,225,000 | $3,800,000 | - | - |
| Payables And Accrued Expenses | $16,500,000 | $17,131,000 | $11,885,000 | $246,444 |
| Payables | $799,000 | $933,000 | $324,829 | $34,444 |
| Accounts Payable | $799,000 | $933,000 | $0 | $34,444 |
| Non Current Deferred Liabilities | - | - | $3,150,000 | $3,150,000 |
| Equity | ||||
| Common Stock Equity | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Total Equity Gross Minority Interest | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Stockholders Equity | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Retained Earnings | $-205,535,000 | $-196,055,000 | $-81,589,000 | $-564,110 |
| Other | ||||
| Ordinary Shares Number | $34,868,628 | $34,649,046 | $33,774,467 | $20,203,440 |
| Share Issued | $34,868,628 | $34,649,046 | $33,774,467 | $20,203,440 |
| Tangible Book Value | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Invested Capital | $-81,316,000 | $-78,645,000 | $-10,043,000 | $105,255,898 |
| Working Capital | $-33,077,000 | $-27,903,000 | $-10,819,000 | $1,303,449 |
| Total Capitalization | $-97,616,000 | $-90,763,000 | $-10,819,000 | $105,255,898 |
| Additional Paid In Capital | $107,919,000 | $105,292,000 | $70,770,000 | $-1,280,265 |
| Capital Stock | $0 | $0 | $0 | $107,100,273 |
| Common Stock | $0 | $0 | $0 | $107,100,273 |
| Current Accrued Expenses | $15,701,000 | $16,198,000 | $11,885,000 | $212,000 |
| Investments And Advances | $90,000 | $3,392,000 | $0 | - |
| Preferred Stock | - | - | $0 | $0 |
| Duefrom Related Parties Current | - | - | $50,000 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,180,000 | $-9,429,000 | $-993,000 | $-1,053,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,180,000 | $-9,429,000 | $-993,000 | $-1,053,000 |
| Cash Flow From Continuing Operating Activities | $-4,180,000 | $-9,429,000 | $-993,000 | $-1,053,000 |
| Operating Gains Losses | $5,369,000 | $88,313,000 | $250,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | - | - | $-2,100,000 | $0 |
| Cash Flow From Continuing Investing Activities | - | - | $-2,100,000 | - |
| Net Other Investing Changes | - | - | $-2,100,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-64,282,000 | $0 | - |
| Issuance Of Capital Stock | $0 | $15,768,000 | $0 | $1,017,000 |
| Financing Cash Flow | $3,400,000 | $10,399,000 | $967,000 | $1,113,000 |
| Cash Flow From Continuing Financing Activities | $3,400,000 | $10,399,000 | $967,000 | $1,113,000 |
| Net Common Stock Issuance | $0 | $-48,514,000 | $0 | $1,017,000 |
| Common Stock Issuance | $0 | $15,768,000 | $0 | $1,017,000 |
| Net Other Financing Charges | - | $52,105,000 | $232,000 | $96,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-2,100,000 | $0 | - |
| Issuance Of Debt | $3,400,000 | $8,908,000 | $735,000 | - |
| End Cash Position | $224,000 | $1,004,000 | $34,000 | $60,000 |
| Beginning Cash Position | $1,004,000 | $34,000 | $60,000 | $0 |
| Changes In Cash | $-780,000 | $970,000 | $-26,000 | $60,000 |
| Common Stock Payments | $0 | $-64,282,000 | $0 | - |
| Net Issuance Payments Of Debt | $3,400,000 | $6,808,000 | $735,000 | - |
| Net Short Term Debt Issuance | $0 | $6,158,000 | $735,000 | - |
| Short Term Debt Payments | $0 | $-2,100,000 | $0 | - |
| Short Term Debt Issuance | $0 | $8,258,000 | $735,000 | - |
| Net Long Term Debt Issuance | $3,400,000 | $650,000 | $0 | - |
| Long Term Debt Issuance | $3,400,000 | $650,000 | $0 | - |
| Change In Working Capital | $1,043,000 | $1,181,000 | $2,809,000 | $4,741,000 |
| Change In Payables And Accrued Expense | $526,000 | $1,700,000 | $2,809,000 | - |
| Change In Accrued Expense | $-343,000 | $467,000 | $0 | - |
| Change In Payable | $869,000 | $1,233,000 | $2,809,000 | - |
| Change In Account Payable | $869,000 | $1,233,000 | $2,809,000 | - |
| Change In Prepaid Assets | $517,000 | $-519,000 | $384,607 | - |
| Other Non Cash Items | $-3,326,000 | $15,509,000 | $929,000 | - |
| Stock Based Compensation | $745,000 | $1,205,000 | $12,378,000 | $56,550,000 |
| Unrealized Gain Loss On Investment Securities | $1,469,000 | $-1,171,000 | $0 | - |
| Earnings Losses From Equity Investments | $3,301,000 | $708,000 | $0 | - |
| Gain Loss On Investment Securities | $1,983,000 | $64,947,000 | $250,000 | - |
| Net Foreign Currency Exchange Gain Loss | $85,000 | $0 | - | - |
| Gain Loss On Sale Of Business | $0 | $7,578,000 | $0 | - |
| Net Income From Continuing Operations | $-9,480,000 | $-114,466,000 | $-17,359,000 | $-62,344,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | - |
| Long Term Debt Payments | - | - | $0 | - |
Fetched: 2026-02-02